Evidence map›Paper›PMID 34926714›Full record

ArticleOpen forum infectious diseases2021

Circulation of Type 2 Vaccine-Derived Poliovirus in China in 2018-2019.

Hehe Zhao, Xiaozhen Ma, Haishu Tang, Yong Zhang, Na Chen, Wusiman Kaisaier, Qi Wang, Cheng Wang, Shuangli Zhu, Qi Qi and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Hehe ZhaoWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Xiaozhen MaSichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
Haishu TangXinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, People's Republic of China.
Yong ZhangWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.ORCID https://orcid.org/0000-0002-2692-5437
Na ChenSichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
Wusiman KaisaierXinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, People's Republic of China.
Qi WangXinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, People's Republic of China.
Cheng WangSichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
Shuangli ZhuWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Qi QiSichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
Yu LiuSichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
Qianli MaSichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
Qing YangSichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
Junhan LiWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Dongyan WangWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Xiaolei LiWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Jinbo XiaoWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Hui ZhuWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Wenbo XuWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Wenbin TongSichuan Center for Disease Control and Prevention, Chengdu, People's Republic of China.
Dongmei YanWHO WPRO Regional Polio Reference Laboratory, NHC Key Laboratory of Biosafety and NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.ORCID https://orcid.org/0000-0002-5558-3018

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChina implemented the globally synchronized switch from trivalent oral poliovirus vaccine (tOPV) to bivalent OPV (bOPV) on May 1, 2016. During April 2018 to May 2019, the first outbreak caused by type 2 circulating vaccine-derived poliovirus (cVDPV2) after the switch occurred in Xinjiang and Sichuan, China.

conclusionsThe detection of this outbreak combined acute flaccid paralysis (AFP) surveillance with environmental surveillance (ES) indicates that ES should be expanded geographically to further complement AFP surveillance.

Indexed as

cVDPV2 outbreakeradicationsurveillancevaccination switch

Identifiers

PMID34926714
PMCPMC8677525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.